Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study

Novita, Bernadette Dian (2018) Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study. Indian Journal of Tuberculosis, 14 (262). pp. 1-6. ISSN 0019-5707

[thumbnail of Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study]
Preview
Text (Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study)
IJTB_262 approval.pdf

Download (467kB) | Preview
[thumbnail of Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study_peer_review]
Preview
Text (Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study_peer_review)
2-R1&2-Metformin_Induced_.pdf

Download (258kB) | Preview
[thumbnail of Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study]
Preview
Text (Metformin Induced Autophagy In Diabetes Mellitus – Tuberculosis Co-Infection Patients: A Case Study)
2-Metformin_induced_Hasil Cek Similarity.pdf

Download (3MB) | Preview

Abstract

Metformin (MET) is a potential combination drug to elevate anti-TB efficacy. However, the clinical effect, especially smear reversion, during metformin applied with anti-tuberculosis and insulin in patients with type 2 DM newly TB co-infection were remain unknown. An observational clinical study was done in DM newly TB co-infection outpatients at Surabaya Paru Hospital. This study evaluated MET therapy, at least 2 months, accompanying with insulin and anti-TB regimens and compared to comparison group. The smear, microtubule-associated Protein1 Light Chain 3B (MAP1LC3B) level, as the presentation of autophagy, Superoxide Dismutase (SOD) level, Interferon (IFN) -γ and Interleukin (IL) -10 levels were evaluated twice. From 42 participants in this study, 22 participants of observation group that received additional MET therapy, 100% had sputum smear reversion after 2-months intensive phase of anti-TB therapy. Whereas 25% of 20 participants of comparison group did not undergo reversion inserts sputum smear. As conclusion, MET has the potential of being an additive combination therapy to enhance the bactericidal effect of anti-TB on DM-TB coinfection patients. Metformin enhances the effects of anti-TB and insulin therapy in increasing the smear reversion by increasing autophagy.

Item Type: Article
Uncontrolled Keywords: type 2 diabetes mellitus-tuberculosis co-infection patients; metformin; AFB smear reversion; and autophagy
Subjects: Medicine
Medicine > RM Therapeutics. Pharmacology
Divisions: Journal Publication
Depositing User: Dr Bernadette Dian Novita Dewi
Date Deposited: 23 Apr 2018 05:59
Last Modified: 22 Feb 2019 01:12
URI: http://repository.ukwms.ac.id/id/eprint/14524

Actions (login required)

View Item View Item